← Back to headlines
Eli Lilly slips as Novo to cut list prices for GLP-1 drugs
Eli Lilly's stock declined after its competitor, Novo Nordisk, announced plans to reduce the list prices for its GLP-1 class of drugs.
24 Feb, 13:12 — 24 Feb, 13:12
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Belgrade Stock Exchange Warns of Online Investment Scam
12m ago
Capital Tankers Plans Oslo Stock Exchange IPO to Raise $345 Million
15m ago
Supernus outlines $840M–$870M 2026 revenue target as ONAPGO supply normalizes and growth brands accelerate
18m ago
Greek Stock Market General Index Rises by 0.72%
23m ago